Physician profile
Paul C Mitchell
NPI 1043232754
$2,048.25
in general payments reported to CMS, 2019-2025
20 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $74.15 · 2021: $352 · 2022: $398 · 2023: $244 · 2024: $378 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $383.96 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $249.37 | 2019-2025 | Clareon, Rocklatan, Simbrinza |
| Sun Pharmaceutical Industries INC. | $191.53 | 2020-2024 | Cequa |
| Oyster Point Pharma, INC. | $186.76 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $178.37 | 2019-2022 | |
| Eyepoint US, INC. | $125.00 | 2019 | |
| Abbvie INC. | $107.78 | 2022-2024 | |
| Quidel Corporation | $98.38 | 2019 | |
| Maculogix, INC. | $88.24 | 2021 | |
| Dompe US, INC. | $77.40 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $67.74 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $60.51 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $54.67 | 2019-2021 | |
| Rxsight INC | $49.64 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $42.71 | 2020-2024 | Catalys System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $26.86 | 2025 | Idosetr |
| Harrow Eye, LLC | $17.95 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.14 | 2021 | |
| Sight Sciences, INC. | $14.45 | 2021 | |
| Horizon Therapeutics Plc | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.